Characteristics of patients with metastatic colorectal cancer.

<p>Characteristics of patients with metastatic colorectal cancer.</p

Evaluation of combination agents in CD-DST.

<p>The in vitro sensitivity was expressed as the T/C ratio, in which T is the total volume of living cancer cells in the treated group, and C is the total volume of living cancer cells in the control group. Positive, T/C <60%; negative, T/C ≥ 60%.</p><p>5-FU, 5-fluorouracil; SN38, the active metabolite of irinotecan; OHP, the active metabolite of oxaliplatin.</p>*<p>statistically significant.</p

Comparison of chemosensitivity between primary site and lung metastasis in CD-DST.

<p>5-FU, 5-fluorouracil; SN38, the active metabolite of irinotecan; OHP, the active metabolite of oxaliplatin.</p><p>There was no significant difference in chemosensitivity when comparing the lung metastasis and the primary tumor.</p